---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-007491"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:55:49.950086+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability

## Summary
- Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.
- GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.
- Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.
- AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).
- Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle.

## SEC filing metadata
- accession: 0001628280-26-007491
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/0001628280-26-007491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/alny-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-007491
- JSON: https://secwatch.observer/filing/0001628280-26-007491.json
- Plain text: https://secwatch.observer/filing/0001628280-26-007491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.